Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126030341 | 12603034 | 1 | I | 20160617 | 20160725 | 20160728 | 20160728 | EXP | FR-AFSSAPS-PC20160421 | FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-48757FF | BOEHRINGER INGELHEIM | 93.96 | YR | F | Y | 50.00000 | KG | 20160728 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126030341 | 12603034 | 1 | PS | PRADAXA | DABIGATRAN ETEXILATE MESYLATE | 1 | Oral | 220 MG | Y | 22512 | 110 | MG | CAPSULE | BID | |||||
| 126030341 | 12603034 | 2 | SS | ALDACTONE | SPIRONOLACTONE | 1 | Oral | 12.5 MG | 0 | 12.5 | MG | COATED TABLET | TIW | ||||||
| 126030341 | 12603034 | 3 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Unknown | 20 MG | 0 | 20 | MG | QD | |||||||
| 126030341 | 12603034 | 4 | SS | BRICANYL | TERBUTALINE SULFATE | 1 | Unknown | 0 | |||||||||||
| 126030341 | 12603034 | 5 | C | LISINOPIL ANHYDRE | 2 | Oral | 10 MG | 0 | 10 | MG | QD | ||||||||
| 126030341 | 12603034 | 6 | C | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | TURBUHALER; STRENGTH: 200/6 MICROGRAM; DOSE PER APPLICATION: 400/12 MCG; DAILY DOSE: 800/24 MCG | 0 | INHALATION POWDER, TABLET | BID | ||||||||
| 126030341 | 12603034 | 7 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 18 MCG | 0 | 18 | UG | INHALATION POWDER, HARD CAPSULE | QD | ||||||
| 126030341 | 12603034 | 8 | C | IMOVANE | ZOPICLONE | 1 | Oral | 3.75 MG | 0 | 3.75 | MG | COATED TABLET | QD | ||||||
| 126030341 | 12603034 | 9 | C | DOLIPRANE | ACETAMINOPHEN | 1 | Unknown | 2 G | 0 | 500 | MG | QID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126030341 | 12603034 | 1 | Thrombosis prophylaxis |
| 126030341 | 12603034 | 2 | Hypertension |
| 126030341 | 12603034 | 3 | Product used for unknown indication |
| 126030341 | 12603034 | 4 | Asthma |
| 126030341 | 12603034 | 5 | Hypertension |
| 126030341 | 12603034 | 6 | Asthma |
| 126030341 | 12603034 | 7 | Asthma |
| 126030341 | 12603034 | 8 | Product used for unknown indication |
| 126030341 | 12603034 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126030341 | 12603034 | DE |
| 126030341 | 12603034 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126030341 | 12603034 | Death | |
| 126030341 | 12603034 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126030341 | 12603034 | 1 | 20160526 | 20160618 | 0 | |
| 126030341 | 12603034 | 2 | 20160526 | 0 | ||
| 126030341 | 12603034 | 3 | 20160615 | 0 | ||
| 126030341 | 12603034 | 4 | 20160615 | 0 | ||
| 126030341 | 12603034 | 5 | 20160412 | 0 | ||
| 126030341 | 12603034 | 6 | 20160412 | 0 | ||
| 126030341 | 12603034 | 7 | 20160412 | 0 | ||
| 126030341 | 12603034 | 8 | 20160412 | 0 | ||
| 126030341 | 12603034 | 9 | 20160412 | 0 |